Investor Presentaiton

Innovation: bepirovirsen - a potential new era in the management of hep B Comprehensive clinical trial programme ongoing Trial Design B-CLEAR Phase II Data presented: EASL', AASLD² NEJM³, 2022 B-CLEAR B-WELL 1 Phase III B-WELL 1 B-WELL 2 B-TOGETHER B-ASSURED Phase III Phase II Data anticipated in 2023 Data anticipated in 2023 B-FINE Biomarker study B-SURE Long term follow up for phase II/III responders 2022 2023 2024 2025 2026 2027 bepirovirsen + nucleot(s)ides 12-24 weeks bepirovirsen + placebo 12-24 weeks bepirovirsen + nucleot(s)ides 24 weeks Baseline HBsAg* <3,000 IU/ml bepirovirsen + nucleot(s)ides 24 weeks B-WELL 2 Baseline HBSAG <3,000 IU/ml B-TOGETHER bepirovirsen 12 or 24 weeks followed by pegylated interferon 24 weeks B-ASSURED Hepatic impairment trial B-FINE bepirovirsen 12w + nucleot(s)ides B-SURE Follow up for partial/full responders from phase II/III trials Additional Phase III studies anticipated to start in 2023 1. European Association for the Study of the Liver, Yuen 2022 2. American Association for the Study of Liver Diseases, Yuen no 38817, Lim no 38809 3. New England Journal of Medicine, Yuen, Lim, 8 Nov 2022 4. Hepatitis B surface antigen GSK 12

View entire presentation